Barr to resubmit Plan B application

Share this article:
Barr Pharmaceuticals will resubmit a request to sell its morning-after contraceptive, Plan B, without a prescription, the company said after meeting with FDA officials last Tuesday. Barr spokeswoman Carol Cox told Reuters the company intends to have a submission back into the FDA in the next two weeks. In a letter sent to Barr earlier this month, the FDA said it would re-examine sales of Plan B without a prescription, proposing that pills would be kept behind pharmacy counters so that women would need to ask for them. Women younger than 18 still would need a prescription. In the letter, the FDA said it hoped to within weeks wrap up Barr's application, which has lingered at the agency since 2003. Cox and FDA spokeswoman Susan Bro described Tuesday’s meeting as “productive.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.